Ciclosporin A Cationic Emulsion 0.1% for the Management of Dry Eye Disease: Facts That Matter for Eye-Care Providers

References

• Akpek EK, Amescua G, Farid M, et al. Dry eye syndrome preferred practice pattern(R). Ophthalmology. 2019;126(1): P286–P334.doi:10.1016/j.ophtha.2018.10.023.
   Web of Science ®Google Scholar
• European Medicines Agency. Ikervis. European public assessment report 2015 updated 16/06/2021. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/ikervis.
   Google Scholar
• US FDA. Drug approval package. Restasis cyclosporine ophthalmic emulsion 2005. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-023_Restasis.cfm.
   Google Scholar
• Deveney T, Asbell PA. Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye. Clin Ophthalmol. 2018;12:569–576. doi:10.2147/OPTH.S115098.
   PubMed Web of Science ®Google Scholar
• Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575–628. doi:10.1016/j.jtos.2017.05.006.
   PubMed Web of Science ®Google Scholar
• Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276–283.doi:10.1016/j.jtos.2017.05.008.
   PubMed Web of Science ®Google Scholar
• Tsubota K, Pflugfelder SC, Liu Z, et al. Defining dry eye from a clinical perspective. Int J Mol Sci. 2020;21(23):9271. doi:10.3390/ijms21239271.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Aragona P, Messmer EM, et al. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. Ocul Surf. 2013;11(4):246–258. doi:10.1016/j.jtos.2013.07.003.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Messmer EM, Aragona P, et al. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol. 2016;100(3):300–306.doi:10.1136/bjophthalmol-2015-307415.
   PubMed Web of Science ®Google Scholar
• Baudouin C. A new approach for better comprehension of diseases of the ocular surface. J Fr Ophtalmol. 2007;30(3):239–246. doi:10.1016/s0181-5512(07)89584-2.
   PubMedGoogle Scholar
• Periman LM, Perez VL, Saban DR, Lin MC, Neri P. The immunological basis of dry eye disease and current topical treatment options. J Ocul Pharmacol Ther. 2020;36(3):137–146. doi:10.1089/jop.2019.0060.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, de Paiva CS. The pathophysiology of dry eye disease: what we know and future directions for research. Ophthalmology. 2017;124(11S):S4–S13. doi:10.1016/j.ophtha.2017.07.010.
   PubMedGoogle Scholar
• de Oliveira RC, Wilson SE. Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease. Clin Ophthalmol. 2019;13:1115–1122. doi:10.2147/OPTH.S184412.
   PubMed Web of Science ®Google Scholar
• Leonardi A, Doan S, Amrane M, et al. A randomized, controlled trial of cyclosporine A cationic emulsion in pediatric vernal keratoconjunctivitis: the VEKTIS study. Ophthalmology. 2019;126(5):671–681. doi:10.1016/j.ophtha.2018.12.027.
   PubMed Web of Science ®Google Scholar
• Bremond-Gignac D, Doan S, Amrane M, et al. Twelve-month results of cyclosporine A cationic emulsion in a randomized study in patients with pediatric vernal keratoconjunctivitis. Am J Ophthalmol. 2020;212:116–126. doi:10.1016/j.ajo.2019.11.020.
   PubMed Web of Science ®Google Scholar
• Shen Lee B, Kabat AG, Bacharach J, Karpecki P, Luchs J. Managing dry eye disease and facilitating realistic patient expectations: a review and appraisal of current therapies. Clin Ophthalmol. 2020;14:119–126. doi:10.2147/OPTH.S228838.
   PubMed Web of Science ®Google Scholar
• White DE, Zhao Y, Ogundele A, et al. Real-world treatment patterns of cyclosporine ophthalmic emulsion and lifitegrast ophthalmic solution among patients with dry eye. Clin Ophthalmol. 2019;13:2285–2292. doi:10.2147/OPTH.S226168.
   PubMed Web of Science ®Google Scholar
• Straub M, Bron AM, Muselier-Mathieu A, Creuzot-Garcher C. Long-term outcome after topical ciclosporin in severe dry eye disease with a 10-year follow-up. Br J Ophthalmol. 2016;100(11):1547–1550. doi:10.1136/bjophthalmol-2015-306930.
   PubMed Web of Science ®Google Scholar
• Levy O, Labbe A, Borderie V, et al. Increased corneal sub-basal nerve density in patients with Sjogren syndrome treated with topical cyclosporine A. Clin Exp Ophthalmol. 2017;45(5):455–463.doi:10.1111/ceo.12898.
   PubMed Web of Science ®Google Scholar
• Baudouin C, de la Maza MS, Amrane M, et al. One-year efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease. Eur J Ophthalmol. 2017;27(6):678–685. doi:10.5301/ejo.5001002.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Figueiredo FC, Messmer EM, et al. A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye. Eur J Ophthalmol. 2017;27(5):520–530. doi:10.5301/EJO.5000952.
   PubMed Web of Science ®Google Scholar
• Labetoulle M, Leonardi A, Amrane M, et al. Persistence of efficacy of 0.1% cyclosporin A cationic emulsion in subjects with severe keratitis due to dry eye disease: a nonrandomized, open-label extension of the SANSIKA study. Clin Ther. 2018;40(11):1894–1906. doi:10.1016/j.clinthera.2018.09.012.
   PubMed Web of Science ®Google Scholar
• Leonardi A, Van Setten G, Amrane M, et al. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 2016;26(4):287–296. doi:10.5301/ejo.5000779.
   PubMed Web of Science ®Google Scholar
• Daull P, Baudouin C, Liang H, et al. Review of preclinical outcomes of a topical cationic emulsion of cyclosporine A for the treatment of ocular surface diseases. Ocul Immunol Inflamm. 2021;1–11. doi:10.1080/09273948.2021.1957124.
   Web of Science ®Google Scholar
• Boboridis KG, Konstas AGP. Evaluating the novel application of cyclosporine 0.1% in ocular surface disease. Expert Opin Pharmacother. 2018;19(9):1027–1039. doi:10.1080/14656566.2018.1479742.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Ciclosporin ophthalmic emulsion 0.1%: a review in severe dry eye disease. Drugs. 2017;77(17):1909–1916. doi:10.1007/s40265-017-0834-x.
   PubMed Web of Science ®Google Scholar
• Kessal K, Liang H, Rabut G, et al. Conjunctival inflammatory gene expression profiling in dry eye disease: correlations with HLA-DRA and HLA-DRB1. Front Immunol. 2018;9:2271. doi:10.3389/fimmu.2018.02271.
   PubMed Web of Science ®Google Scholar
• Leonardi A, Messmer EM, Labetoulle M, et al. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies. Br J Ophthalmol. 2019;103(1):125–131. doi:10.1136/bjophthalmol-2017-311801.
   PubMed Web of Science ®Google Scholar
• Periman LM, Mah FS, Karpecki PM. A review of the mechanism of action of cyclosporine A: the role of cyclosporine A in dry eye disease and recent formulation developments. Clin Ophthalmol. 2020;14:4187–4200. doi:10.2147/OPTH.S279051.
   PubMed Web of Science ®Google Scholar
• Kim J, Moon TK, Yoon HJ, Ji YS, Yoon KC. Efficacy of switching from cyclosporine A 0.05% anionic emulsion to cyclosporine A 0.1% cationic emulsion in patients with dry eye associated with Sjogren’s syndrome. J Ocul Pharmacol Ther. 2021;37(8):472–478. doi:10.1089/jop.2020.0146.
   PubMed Web of Science ®Google Scholar
• Pisella PJ, Labetoulle M, Doan S, et al. Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program. Clin Ophthalmol. 2018;12:289–299. doi:10.2147/OPTH.S150957.
   PubMed Web of Science ®Google Scholar
• Hind J, Macdonald E, Lockington D. Real-world experience at a Scottish university teaching hospital regarding the tolerability and persistence with topical ciclosporin 0.1% (Ikervis) treatment in patients with dry eye disease. Eye (Lond). 2019;33(4):685–686. doi:10.1038/s41433-018-0289-7.
   PubMed Web of Science ®Google Scholar
• Geerling G, Hamada S, Trocmé S, et al. Real-world effectiveness, tolerability and safety of cyclosporine A 0.1% cationic emulsion in severe keratitis and dry eye treatment. Ophthalmol Ther. 2022;11(3):1101–1117.
   Google Scholar
• Deshmukh R, Ting DSJ, Elsahn A, et al. Real-world experience of using ciclosporin-A 0.1% (Ikervis) in the management of ocular surface inflammatory diseases. Br J Ophthalmol. 2021. doi:10.1136/bjophthalmol-2020-317907.
   Web of Science ®Google Scholar